MEP38708A - Use of hcg and lh in controlled ovarian hyperstimulation - Google Patents

Use of hcg and lh in controlled ovarian hyperstimulation

Info

Publication number
MEP38708A
MEP38708A MEP-387/08A MEP38708A MEP38708A ME P38708 A MEP38708 A ME P38708A ME P38708 A MEP38708 A ME P38708A ME P38708 A MEP38708 A ME P38708A
Authority
ME
Montenegro
Prior art keywords
hcg
ovarian hyperstimulation
controlled ovarian
rates
decreased
Prior art date
Application number
MEP-387/08A
Other languages
Bosnian (bs)
English (en)
Croatian (hr)
Inventor
Yves Menezo
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8182262&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MEP38708(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Publication of MEP38708A publication Critical patent/MEP38708A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/11—Gonadotropin; related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/13—Luteinizing hormone-releasing hormone; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Reproductive Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
MEP-387/08A 2001-09-12 2002-09-12 Use of hcg and lh in controlled ovarian hyperstimulation MEP38708A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01307758 2001-09-12
PCT/GB2002/004167 WO2003022303A2 (en) 2001-09-12 2002-09-12 Use of hcg and lh in controlled ovarian hyperstimulation

Publications (1)

Publication Number Publication Date
MEP38708A true MEP38708A (en) 2011-02-10

Family

ID=8182262

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-387/08A MEP38708A (en) 2001-09-12 2002-09-12 Use of hcg and lh in controlled ovarian hyperstimulation

Country Status (27)

Country Link
US (1) US7402558B2 (xx)
EP (1) EP1425033B1 (xx)
JP (1) JP2005501919A (xx)
KR (1) KR20040032952A (xx)
CN (1) CN100376289C (xx)
AR (1) AR036593A1 (xx)
AT (1) ATE489964T1 (xx)
BR (1) BR0212447A (xx)
CA (1) CA2457851A1 (xx)
CY (1) CY1110991T1 (xx)
DE (1) DE60238490D1 (xx)
DK (1) DK1425033T3 (xx)
EA (1) EA009279B1 (xx)
ES (1) ES2356895T3 (xx)
HK (1) HK1067865A1 (xx)
HR (1) HRP20040086A2 (xx)
IL (1) IL160782A0 (xx)
ME (1) MEP38708A (xx)
MX (1) MXPA04002257A (xx)
NO (1) NO327153B1 (xx)
PL (1) PL369021A1 (xx)
PT (1) PT1425033E (xx)
SI (1) SI1425033T1 (xx)
UA (1) UA82052C2 (xx)
WO (1) WO2003022303A2 (xx)
YU (1) YU21104A (xx)
ZA (1) ZA200400781B (xx)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040248784A1 (en) * 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
GB0723882D0 (en) * 2007-12-07 2008-01-23 Univ Leicester Methods for the detection of a threatened miscarriage
AU2012286048A1 (en) 2011-07-18 2014-02-20 Arts Biologics A/S Long acting luteinizing hormone (LH) compound
WO2014159813A1 (en) 2013-03-13 2014-10-02 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
ES2716862T3 (es) * 2014-12-22 2019-06-17 Ferring Bv Terapia con antagonistas del receptor de oxitocina en la fase lútea para la implantación y embarazo en mujeres que se someten a tecnologías de reproducción asistida
FI3261661T3 (fi) 2015-02-26 2024-01-15 Ferring Bv Menotropiini hedelmättömyyden hoitamiseksi
US11185569B2 (en) * 2016-05-04 2021-11-30 University Of Cincinnati ActRIIB:Fc to treat infertility in females
TWI846743B (zh) * 2018-10-17 2024-07-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法
CN110041436A (zh) * 2019-04-28 2019-07-23 广州威生医药科技有限公司 长效重组fsh融合蛋白在母猪批次化生产中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4589402A (en) 1984-07-26 1986-05-20 Serono Laboratories, Inc. Method of in vitro fertilization
US5705478A (en) * 1989-02-21 1998-01-06 Washington University Covalently linked β subunits of the glycoprotein hormones as antagonists
FR2744367B1 (fr) * 1996-02-02 1999-07-09 Emperaire Jean Claude Medicaments pour le declenchement de l'ovulation
WO1998058657A1 (en) * 1997-06-20 1998-12-30 Akzo Nobel N.V. Gonadotropin releasing hormone antagonist
ZA987497B (en) * 1997-09-08 1999-02-23 Akzo Nobel Nv Expression of gonadotropins in dictyostelium
US6090848A (en) * 1997-12-01 2000-07-18 Sigma-Tau Healthscience S.P.A. Compositions and methods for increasing the concentration and/or motility of spermatozoa in humans
KR20010093280A (ko) * 1999-02-24 2001-10-27 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 불임증 치료
SI1176976T2 (sl) * 1999-05-07 2015-12-31 Merck Serono Sa Uporaba LH, dajanega v srednji ali pozni folikularni fazi, za zdravljenje anovulatornih žensk
PL211113B1 (pl) * 2000-01-27 2012-04-30 Serono Lab Zastosowanie FSH do leczenia bezpłodności
US6953774B2 (en) * 2000-08-11 2005-10-11 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation

Also Published As

Publication number Publication date
MXPA04002257A (es) 2004-07-23
CY1110991T1 (el) 2015-06-11
YU21104A (sh) 2006-08-17
JP2005501919A (ja) 2005-01-20
US7402558B2 (en) 2008-07-22
DK1425033T3 (da) 2011-01-10
CN1553810A (zh) 2004-12-08
WO2003022303A3 (en) 2003-12-18
HRP20040086A2 (en) 2004-12-31
NO327153B1 (no) 2009-05-04
PT1425033E (pt) 2010-12-29
CA2457851A1 (en) 2003-03-20
SI1425033T1 (sl) 2011-01-31
ES2356895T3 (es) 2011-04-14
WO2003022303A2 (en) 2003-03-20
DE60238490D1 (de) 2011-01-13
CN100376289C (zh) 2008-03-26
BR0212447A (pt) 2004-08-17
NO20040962L (no) 2004-03-05
AR036593A1 (es) 2004-09-22
HK1067865A1 (en) 2005-04-22
EA200400426A1 (ru) 2004-08-26
ZA200400781B (en) 2005-04-26
EP1425033B1 (en) 2010-12-01
ATE489964T1 (de) 2010-12-15
EP1425033A2 (en) 2004-06-09
EA009279B1 (ru) 2007-12-28
PL369021A1 (en) 2005-04-18
UA82052C2 (uk) 2008-03-11
US20050020489A1 (en) 2005-01-27
IL160782A0 (en) 2004-08-31
KR20040032952A (ko) 2004-04-17

Similar Documents

Publication Publication Date Title
MEP39208A (en) USE OF hCG IN CONTROLLED OVARIAN HYPERSTIMULATION
SE0100901D0 (sv) New composition
HK1067865A1 (en) Use of hcg and lh in controlled ovarian hyperstimulation
CY2014038I2 (el) Αντι-il-6 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
PA8565101A1 (es) Formas de dosificacion farmaceutica de liberacion controlada de un inhibidor de la proteina de transferencia de ester de colesterilo
IL156774A0 (en) Inhibitors of cruzipain and other cysteine proteases
CY1112957T1 (el) Μη νευροτοξικοι παραγοντες, οι οποιοι ενεργοποιουν το πλασμινογονο για τη θεραπευτικη αγωγη εγκεφαλικου επεισοδιου
DK1262236T3 (da) Fremgangsmåde til fremstilling af formet legeme af alfa-alumina
DK1383742T3 (da) Syntese og fremgangsmåder til anvendelse af tetrahydroindolonanaloge og derivater
ATE292966T1 (de) Methode zur synthetisierung von leflunomid
NO20040990L (no) Andvendelse av LH i kontrollert ovariehyperstimulering.
ES2218407T3 (es) Uso de oxazolidinonas tiamida para el tratamiento de la resorcion osea y la osteoporosis.
ATE277924T1 (de) Aryl-8-azabicyclo(3.2.1)octanes für die behandlung von depression
BR0117078B1 (pt) mÉtodo para preparaÇço de couro utilizando protease e mÉtodo para tratamento de dejetos derivados do processamento do couro utilizando o mesmo.
DK1126853T3 (da) Kontrolleret levering af antidepressine midler
SE0100374D0 (sv) Novel compositions of potassium channel openers and protein kinase c inhibitors and use thereof
WO2002057248A3 (en) Inhibitors of cruzipain and other cysteine proteases
ATA9412000A (de) Einrichtung, insbesondere brenner zur erzeugung von plasma
ATE433953T1 (de) Peptiddeformylaseinhibitoren
FR2832627B1 (fr) Composition cosmetique pour le traitement des poils, dont cheveux, et des follicules pileux
MXPA01009174A (es) Antagonistas de endotelina novedosos derivados de piridazina.
DK1438341T3 (da) Antistoffer som stimulerer produktionen af IL-1Ra
ES1050413Y (es) Prensador para elaboracion de salazones y analogos.
PT1383512E (pt) Utilizacao de sucralfato para o tratamento de erosao cervical
BR0104878B1 (pt) vaporizador direcional de uso humano.